NantKwest, Inc. (NASDAQ:NK) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders. |
We held our 2017 annual meeting of stockholders on June9, 2017
(the Annual Meeting). Of the 82,155,862shares of our common stock
outstanding as of the record date of April17, 2017, 73,839,241
shares were represented at the Annual Meeting, either in person
or by proxy, constituting approximately 89.88% of the outstanding
shares of common stock. The matters voted on at the Annual
Meeting and the votes cast with respect to each such matter are
set forth below:
| 1. |
Election of Directors. Each of the following nominees was elected to serve as a director, to hold office until our 2018 annual meeting of stockholders and until his respective successor has been duly elected and qualified based on the following results of voting: |
|
Nominee |
Votes For | VotesWithheld | BrokerNon-Votes | |||||||||
|
Patrick Soon-Shiong |
59,365,083 | 5,926,006 | 8,548,152 | |||||||||
|
Barry J. Simon |
59,282,537 | 6,008,552 | 8,548,152 | |||||||||
|
Steve Gorlin |
63,714,303 | 1,576,786 | 8,548,152 | |||||||||
|
Michael D. Blaszyk |
64,500,342 | 790,747 | 8,548,152 | |||||||||
|
Richard Kusserow |
64,325,607 | 965,482 | 8,548,152 | |||||||||
|
John T. Potts, Jr. |
64,410,791 | 880,298 | 8,548,152 | |||||||||
|
John C. Thomas, Jr. |
64,322,550 | 968,539 | 8,548,152 |
| 2. |
Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of Ernst Young LLP as our independent registered public accounting firm for the fiscal year ending December31, 2017 was ratified based on the following results of voting: |
|
For |
Against |
Abstentions |
BrokerNon-Votes |
|||
| 73,606,884 | 220,389 | 11,968 |
About NantKwest, Inc. (NASDAQ:NK)
NantKwest, Inc., formerly Conkwest, Inc., is a biotechnology company engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Company is focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases. Its product candidates include activated NK cells (aNK), high-affinity NKs (haNKs) and target activated Natural Killers (taNKs). It develops aNK product candidates for the treatment of virally-induced cancers, such as polyoma virus induced Merkel Cell Carcinoma, Human Papilloma Virus induced cervical, and head and neck cancers, as well as infectious diseases, such as Ebola and other serious viral, fungal and bacterial infections. It also develops haNKs for the treatment of solid tumors, breast cancer, multiple myeloma, lymphoma and colorectal cancer, and taNKs for the treatment of brain cancer, breast cancer, non-hodgkin lymphoma and myelodysplastic syndrome.